13 May 2025
13 May 2025
US President Donald Trump has signed an executive order telling drugmakers to cut prices to "most favoured nation" pricing.
Non-partisan think tank CBO estimates that the plans could result in 13.4 million Americans losing their health insurance by 2034.
Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.
GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033.
The Phase III trial of the drug received a $17m grant from the Cancer Prevention Research Institute of Texas.
Novo Nordisk sought approval in April 2025 for Sogroya in three paediatric growth disorder indications.
The new site will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines.
The approval was based on the propellant clinical development programme outcomes.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
